Program
zabadinostat
Also written as “Zabadinostat (CXD101)” and “CXD101 in Combination With Nivolumab”.
Its studies are mostly in Pancreatic Neoplasms · Colonic Neoplasms, led by 2 companies.
Drug pageZabadinostat: every studyAll 5 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Celleron Therapeuticsits history only | 10 open or running | phase 2since Jun 19, 2019 | Jun 19, 2019 | none ahead |
| ImmunityBioits history only | 10 open or running | phase 1since Nov 20, 2025 | Nov 20, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 19, 2019First study: phase 2 study in Colonic NeoplasmsNew to Celleron TherapeuticsCelleron Therapeutics · NCT03993626 · 55 enrolled · United Kingdom
- Jul 21, 2022Named zabadinostatINNProposed as its International Nonproprietary Name in WHO's List 127
- Nov 20, 2025ImmunityBio’s first study: phase 1 study in Pancreatic NeoplasmsNew to ImmunityBioImmunityBio · NCT07488884
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07488884Pancreatic Neoplasms | 1 | Withdrawn | ImmunityBio | Jun 1, 2027 | 0 |
| NCT03993626Colonic Neoplasms · United Kingdom | 2 | UNKNOWN | Celleron Therapeutics | Dec 15, 2019 | 55 |
How it is read
Names in the registry
- “Zabadinostat (CXD101)”, 1 entry
- “CXD101 in Combination With Nivolumab”, 1 entry
Conditions, from the studies’ own filings
- Pancreatic Neoplasms, 1 study
- Colonic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.